三生国健：辉瑞在某网站上登记PD-1/VEGF双抗PF-08634404(SSGJ-707)的两项全球III期临床试验其最终付款尚存在不确定性

Core Viewpoint - Sanofi has granted Pfizer exclusive rights for the development, production, and commercialization of the dual-specific antibody product targeting PD-1 and VEGF, known as project 707, for both human and veterinary uses [1] Group 1: Licensing Agreement - The licensing agreement between Sanofi and Pfizer will officially take effect on July 24, 2025 [1] - The agreement covers all therapeutic, diagnostic, and preventive indications within the licensed area [1] - Payments from Pfizer to Sanofi will be distributed between the company and Shenyang Sanofi [1] Group 2: Clinical Trials - Pfizer has registered two global Phase III clinical trials for the PD-1/VEGF dual antibody PF-08634404 (SSGJ-707) on ClinicalTrials.gov as of October 30, 2025 [1] - The milestone payments outlined in the licensing agreement are contingent upon meeting specific conditions, leading to uncertainty regarding final payments [1]